MDMA in PTSD
February 13, 2019 DOI: 10.64239/pi-qt0303
Summary
MDMA showed a very strong effect size when used at full dose compared to a small-dose active control during two therapy sessions, which were one month apart. Participants also received 18 hours of manual-driven psychotherapy without MDMA. While MDMA is not intended for routine use with patients, the results indicate promising potential for its adjunctive use in therapy, paving the way for future phase III clinical trials.
Study at a glance
| Key finding | MDMA exhibited a very strong effect size at full dose relative to a small-dose active control. |
|---|
Abstract
As just one of several psychotropics being examined for potential adjunctive use with psychotherapy, MDMA exhibited a very strong effect size at full dose relative to a small-dose “active control." It was used in two therapy sessions, 1 month apart, in addition to 18 hours of psychotherapy without MDMA–all of which was manual driven. Although MDMA is not going to be used routinely with our patients, it’s interesting to see that this work is being performed, and the results were striking. Watch for phase III clinical trials to follow based on this work.